Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 662 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nicotinic acid Clear all
Completed No phase listed Observational Accepts healthy volunteers

Observational Metabolic Health Study

NCT06790407
View directory record Official record
Conditions
Healthy
Interventions
Mimio Study Product, Placebo
Dietary Supplement
Lead sponsor
Mimio Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Not applicable Interventional

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

NCT00046267
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions
Niacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

NCT00908167
View directory record Official record
Conditions
Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, Biphenotypic Leukemia
Interventions
Sorafenib, Cytarabine, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 31 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

NCT02196857
View directory record Official record
Conditions
Leukemia
Interventions
Azacytidine, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 9, 2026, 1:56 AM EDT
Not listed Phase 2 Interventional

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

NCT01265576
View directory record Official record
Conditions
HCC
Interventions
Sorafenib, VT-122 (propranolol plus etodolac), Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 9, 2026, 1:56 AM EDT
Recruiting Phase 2 Interventional

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

NCT07013591
View directory record Official record
Conditions
Cardiac Surgery
Interventions
MIB-626, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Pharmacokinetic Study of Nicotinamide Riboside"

NCT02689882
View directory record Official record
Conditions
Metabolic Disturbance
Interventions
nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

NCT01075113
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, vorinostat
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 9, 2026, 1:56 AM EDT
Completed No phase listed Observational

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

NCT01178320
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Simvastatin, simvastatin plus extended-release niacin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

NCT03865927
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo Oral Tablet, GKT137831
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 9, 2026, 1:56 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00726986
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, sorafenib tosylate
Drug
Lead sponsor
Afshin Dowlati, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
New York, New York • Cleveland, Ohio • Mayfield Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 9, 2026, 1:56 AM EDT
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Micronutrient Supplementation and Infant Survival

NCT00860470
View directory record Official record
Conditions
Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality, Perinatal Mortality
Interventions
Iron (27 mg) - folic acid (600 ug), Multiple micronutrient
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
44,567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 9, 2026, 1:56 AM EDT
Terminated Phase 1 Interventional Results available

Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)

NCT05457491
View directory record Official record
Conditions
Skin Aging
Interventions
Human platelet extract (cosmetic product), Vanicream Gentle Facial Cleanser, EltaMD UV Daily Broad-Spectrum SPF 40, EltaMD PM Therapy Facial Moisturizer, Vanicream Lite Lotion
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

NCT02258074
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide, Lanthanum Carbonate, Placebo (for Nicotinamide), Placebo (for lanthanum carbonate)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

NCT00303797
View directory record Official record
Conditions
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 9, 2026, 1:56 AM EDT
Terminated Phase 3 Interventional Results available

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

NCT02460991
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
Interventions
DEB-TACE, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 9, 2026, 1:56 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

NCT01334710
View directory record Official record
Conditions
Liver Cancer
Interventions
Sorafenib and OSI-906
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 9, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

NCT05947383
View directory record Official record
Conditions
Cancer, Major Depressive Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 9, 2026, 1:56 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 9, 2026, 1:56 AM EDT
Recruiting Phase 2 Interventional

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

NCT07579429
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome
Interventions
Nicotinamide Riboside, Pterostilbene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 9, 2026, 1:56 AM EDT
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 9, 2026, 1:56 AM EDT